Last reviewed · How we verify

NCT03637673

The Possible Role of Thyroxine in Keratoconus Development

Status unknown Last updated 20 August 2018
What this trial tests

trial testing No intervention in Keratoconus in 150 participants. Status unknown.

Timeline
1 June 2018
Primary endpoint
30 August 2018
15 September 2018

Quick facts

Lead sponsorAlexandria University
StatusStatus unknown
Study typeOBSERVATIONAL
Enrollment150
Start date1 June 2018
Primary completion30 August 2018
Estimated completion15 September 2018
Sites1 location across Egypt

Drugs / interventions tested

Conditions studied

Sponsor

Alexandria University

Who can join

Adults 18 to 100, any sex, with Keratoconus. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

Keratoconus (KC) is a corneal ectatic disorders, with incidence rate 1 per 50,000 among the population. Hormonal imbalances may be associated with KC as it affects the corneal metabolism. In this study, we aim to examine this clinical association between thyroid gland dysfunction (TGD) and KC.

Publications & conference data

No peer-reviewed publications indexed yet for this trial.

Verify or expand the search:

Other trials of No intervention

Trials testing the same drug.

Other recruiting trials for Keratoconus

Currently open trials in the same condition.

Other Alexandria University trials

Trials by the same sponsor.

Verify against primary sources

Data sources for this page

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT03637673.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing